Keywords: مهار کننده های بازرسی; Urothelial carcinoma; Bladder cancer; Immunotherapy; Checkpoint inhibitors; Chemotherapy; Clinical trials; Targeted therapy; Platinum ineligible;
مقالات ISI مهار کننده های بازرسی (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Ipilimumab; Pembrolizumab; Nivolumab; Autoimmunity; Rheumatic manifestations; Psoriatic arthritis; Rheumatoid arthritis; Eosinophilic fasciitis; Sarcoidosis;
Keywords: مهار کننده های بازرسی; Myelodysplastic syndromes; Autoimmune diseases; Immunosuppressive therapy; Checkpoint inhibitors; Hypomethylating agents;
Keywords: مهار کننده های بازرسی; PMH; past medical history; ROS; review of systems; WNL; within normal limits; C; cycle; BP; blood pressure; UTI; urinary tract infection; NIDDM; non-insulin-dependent diabetes mellitus; Advanced cervical cancer; Metastatic cervical cancer; Recurrent cervi
Keywords: مهار کننده های بازرسی; Immune tolerance; Vaccination; Dendritic cells; Hematologic malignancy; Checkpoint inhibitors; CAR-T; IMiDs;
Keywords: مهار کننده های بازرسی; PD-1; PD-L1; Immunotherapy; Checkpoint inhibitors; Biomarkers; Non-small cell lung cancer; Tumor mutational burden; Microbiome;
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Immune-related adverse events; Sarcoidosis-like reactions;
Keywords: مهار کننده های بازرسی; Brentuximab vedotin; checkpoint inhibitors; nivolumab; pembrolizumab; transplant;
Keywords: مهار کننده های بازرسی; Melanoma; Checkpoint inhibitors; Ipilimumab; Nivolumab; Pembrolizumab; Immune-related adverse events;
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Immunotherapy; Lymphocyte count; NSCLC; Response rate;
Keywords: مهار کننده های بازرسی; Renal cell carcinoma; Immunotherapy; Checkpoint inhibitors; Kidney cancer; Targeted therapy;
Keywords: مهار کننده های بازرسی; Immunotherapy; Checkpoint inhibitors; Urothelial carcinoma;
Keywords: مهار کننده های بازرسی; TNF-α; tumor necrosis factor-alpha; IL1; interleukin-1; IFN-α; interferon-alpha; FOXP3; forkhead box P3; ROR; RAR-related orphan receptor gamma; Probiotics; Gut microbiota; Cancer immunotherapies; Tumor immunology; Checkpoint inhibitors; PD-1; PDL-1; CT
Keywords: مهار کننده های بازرسی; Nasopharyngeal carcinoma; Recurrent; Metastatic; Chemotherapy; Targeted therapy; Immunotherapy; Checkpoint inhibitors;
Keywords: مهار کننده های بازرسی; Acute myeloid leukemia; Acute lymphoblastic leukemia; Immunotherapy; Checkpoint inhibitors; BiTEs; Antibody-drug conjugates; Inotuzumab; Blinatumomab; CART cells;
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Immune-related adverse events; Meta-analysis; Systematic review; Clinical trials;
Keywords: مهار کننده های بازرسی; Non-small cell lung cancer; Chemotherapy; Immunotherapy; Checkpoint inhibitors; PD-1; Response rate;
Keywords: مهار کننده های بازرسی; Multiple myeloma; Immunotherapy; Monoclonal antibodies; Chimeric antigen receptor (CAR) T cells; Checkpoint inhibitors; Allogeneic stem cell transplantation;
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Co-stimulatory agonists; Cell therapy; Vaccines; Virus; Combination;
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Ipilimumab; Pembrolizumab; Nivolumab; Organ transplantation; Rejection;
Keywords: مهار کننده های بازرسی; Immunotherapy; Autologous stem cell transplantation; Checkpoint inhibitors; Lymphoma; Myeloma; Adoptive cell therapy
Keywords: مهار کننده های بازرسی; Immunotherapy; Autologous stem cell transplantation; Checkpoint inhibitors; Lymphoma; Myeloma; Adoptive cell therapy
Keywords: مهار کننده های بازرسی; Bladder cancer; Urothelial carcinoma; Immune therapy; Checkpoint inhibitors; Clinical trials;
Keywords: مهار کننده های بازرسی; Immunotherapy; Checkpoint inhibitors; Radiation therapy; Stereotactic radiosurgery
Keywords: مهار کننده های بازرسی; Immunotherapy; Ovarian cancer; Cervical cancer; Endometrial cancer; Gynecologic cancers; Checkpoint inhibitors; Immuno-oncology
Keywords: مهار کننده های بازرسی; Gastrointestinal cancer; Immunotherapy; Checkpoint inhibitors
Keywords: مهار کننده های بازرسی; cancer therapy; checkpoint inhibitors; drug development; immunotherapy; lung cancer; next-generation sequencing; precision oncology; targeted therapy;
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Chemotherapy; Clinical trials; Incidence; Merkel cell polyomavirus;
Keywords: مهار کننده های بازرسی; Non-small-cell lung cancer; Immune system; Immunotherapy; Checkpoint inhibitors; Cancer vaccines;
Keywords: مهار کننده های بازرسی; Bladder cancer; Checkpoint inhibitors; 5H1; PD-1; PD-L1
Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Pembrolizumab; Immunotherapy; Anti-PD-1; Melanoma; Sarcoidosis;
Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer
Keywords: مهار کننده های بازرسی; Bladder cancer; Immunotherapy; Checkpoint inhibitors; BCG;
How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT
Keywords: مهار کننده های بازرسی; Brentuximab vedotin; Checkpoint inhibitors; Haploidentical; Nivolumab; Pembrolizumab;
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Keywords: مهار کننده های بازرسی; Immunooncology; Checkpoint inhibitors; Companion diagnostics; Complementary diagnostics; Cytology; Pathology;
Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients
Keywords: مهار کننده های بازرسی; AC; Biomarker; Bladder cancer; Checkpoint inhibitors; Immunotherapy;
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
Keywords: مهار کننده های بازرسی; Lung cancer; NSCLC; Checkpoint inhibitors; Biomarkers; PD-L1;
Checkpoint inhibitors as treatment for malignant gliomas: “A long way to the top”
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Immunotherapy; Malignant gliomas; Glioblastoma; PD-1; PD-L1;
Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors
Keywords: مهار کننده های بازرسی; CAR-T cells; Checkpoint inhibitors; Chimeric antigen receptor; Immune-oncology; Multiple myeloma;
Original ResearchDutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands
Keywords: مهار کننده های بازرسی; Quality assurance; Metastatic melanoma; Checkpoint inhibitors; MAP kinase inhibitors; Population-based; Registry; Ipilimumab;
Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy
Keywords: مهار کننده های بازرسی; Pneumonitis; Anti-PD-1; Anti-CTLA-4; Checkpoint inhibitors; Immunotherapy; Immune-related adverse events;
Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; Immunotherapy; PD-1; PD-L1; T cells;
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Keywords: مهار کننده های بازرسی; PD-1; PD-L1; Checkpoint inhibitors; Primary resistance; Acquired resistance;
Targeting DNA damage in SCLC
Keywords: مهار کننده های بازرسی; Lung Cancer; Small Cell Lung Cancer; DNA Repair Pathways; PARP Inhibitors; Checkpoint Inhibitors;
Health-related quality of life results from the phase III CheckMate 067 study
Keywords: مهار کننده های بازرسی; Health-related quality of life; Checkpoint inhibitors; Advanced melanoma; Nivolumab; Ipilimumab;
ReviewOpportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge
Keywords: مهار کننده های بازرسی; Autoimmunity; Immunotherapy; Cancer; Opportunistic; Checkpoint inhibitors;
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy
Keywords: مهار کننده های بازرسی; PET; FET; MET; FDOPA; Glioma; Temozolomide; Bevacizumab; Immunotherapy; Checkpoint inhibitors; Pseudoprogression; Pseudoresponse;
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors
Keywords: مهار کننده های بازرسی; Ibrutinib; Bruton tirosine kinase; Solid tumors; Checkpoint inhibitors; Tumor microenvironment; TEC kinases;
What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma
Keywords: مهار کننده های بازرسی; Checkpoint inhibitors; HL; Nivolumab; Programmed death inhibitor; Transplant;
Réponse prolongée sous paclitaxel après immunothérapie par pembrolizumab dans le cancer bronchique
Keywords: مهار کننده های بازرسی; Immunothérapie; Inhibiteurs des points de contrôle immunologiques; Pembrolizumab; Cancer bronchique non à petites cellules avancé; Immunotherapy; Checkpoint inhibitors; Pembrolizumab; Advanced non-small-cell lung cancer;
ReviewTurning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
Keywords: مهار کننده های بازرسی; Cancer; Immunotherapy; Checkpoint inhibitors; Antigen presentation;